• Keval Thakkar, Adnan Rafiq Karajgi, Anusha Manoj Kallamvalappil, Chaithanya Avanthika, Sharan Jhaveri, Arundhati Shandilya, AnusheelRyazan State I P Pavlov Medical Institute, Ryazan, Russia., and Rayan Al-Masri.
• G.M.E.R.S. Medical College and General Hospital, Gandhinagar, India.
• Dis Mon. 2023 Apr 1; 69 (4): 101548101548.

AbstractThe most prevalent cause of mortality in children with hypertrophic cardiomyopathy (HCM) is sudden cardiac death (SCD), which happens more frequently than in adult patients. Risk stratification tactics have generally been drawn from adult practice, however emerging data has revealed significant disparities between children and adult cohorts, implying the need for pediatric-specific risk stratification methodologies. We conducted an all-language literature search on Medline, Cochrane, Embase, and Google Scholar until October 2021. The following search strings and Medical Subject Heading (MeSH) terms were used: "HCM," "SCD," "Sudden Cardiac Death," and "Childhood Onset HCM." We explored the literature on the risk of SCD in HCM for its epidemiology, pathophysiology, the role of various genes and their influence, associated complications leading to SCD and preventive and treatment modalities. Childhood-onset HCM is linked to significant life-long morbidity and mortality, including a higher SCD rate in children than in adults. The present focus is on symptom relief and avoiding illness-related consequences, but the prospect of future disease-modifying medicines offers an intriguing opportunity to alter disease expression and outcomes in these young individuals. Current preventive recommendations promote implantable cardioverter defibrillator placement based on cumulative risk factor thresholds, although they have been demonstrated to have weak discriminating capacity. This article addresses questions and discusses the etiology, risk factors, and method to risk stratification for SCD in children with HCM.Copyright © 2023 Elsevier Inc. All rights reserved.

23 keywords...

hide…